{"ticker": {"uuid": "1ae867c3-c06f-4000-8717-f608959a1835", "symbol": "ALVO", "name": "Alvotech", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "ALVO Stock Price Prediction 2025-2026 | Alvotech Forecast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE5wOWRJSkhhdF95ck1DR3NrcmFDV2ZiUDFjWVVuTjZxYVB1RllDZC1oR2FFajNDZWJudVhjYll6akhXVk96cHU1X2VoMkhnTkxRWHJ1alVhNUxfN2N4cVdsZkMzUzY?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-07-15T15:07:47+00:00", "published_display": "15 Jul 2026 15:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (ALVO) Could Be 76% Below Fair Value On New $75 Million Debt Facility", "summary": "Alvotech (ALVO) has recently secured a new $75 million debt facility and raised $165 million in equity, providing $240 million for its biosimilar pipeline and commercialization. Despite this new capital, the company's stock has faced significant pressure, falling over 60% in the ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alvo/alvotech/news/alvotech-alvo-could-be-76-below-fair-value-on-new-75-million", "source_name": "Simply Wall Street", "published_at": "2026-07-15T09:13:18", "published_display": "15 Jul 2026 09:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (NASDAQ:ALVO) Shares Down 5.5% - Here's What Happened", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPWnlkaWwyYmYtOVlTNkhTbFJITzNyUGo3RWZIa2NNc05ydmw0Q3k0a0ktSU5QTEs0MTJEVE9IeFd4NDVhYzgxMjZEMWJsekZFeUxOWUcwSDF0bXBiekhhVFpiSXVCS20xNXNnVHMxMDlKeWVlQ1RlX2x6WDAwNDd4bXZnTy1JazVhQ2IwLXJORjVOZUZsSklDdDFob0hvMXNhWk1BbXVhRDR3T1FE?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-14T17:49:55+00:00", "published_display": "14 Jul 2026 17:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (ALVO) Barclays 27th Annual Global Healthcare Conference 2025 Summary", "summary": "This article summarizes Alvotech's presentation at the Barclays 27th Annual Global Healthcare Conference 2025, highlighting its focus on biosimilars, global reach, and financial projections. Key points include an expected 2025 revenue of $600\u2013$800 million, strong performance of i", "url": "https://quartr.com/events/alvotech-alvo-barclays-27th-annual-global-healthcare-conference-2025_F3vP6ngK", "source_name": "Quartr", "published_at": "2026-07-13T17:11:30", "published_display": "13 Jul 2026 17:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Alvotech Stocks", "summary": "This article lists various ETFs that hold shares of Alvotech (ALVO), a biotechnology company. It provides details such as the market value of Alvotech stocks within each ETF, their weight, issuer, management style, expense ratio, and assets under management. The information aims ", "url": "https://www.tradingview.com/symbols/OMXICE-ALVO/etfs/", "source_name": "TradingView", "published_at": "2026-07-12T21:10:42", "published_display": "12 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Alvotech \u2013 NASDAQ:ALVO", "summary": "This page provides financial information for Alvotech (NASDAQ: ALVO), specifically focusing on its enterprise value to EBITDA forward metric. It indicates that the market was closed at the time of the data display. The page is part of TradingView's financial analysis tools, offer", "url": "https://www.tradingview.com/symbols/NASDAQ-ALVO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T12:39:17", "published_display": "10 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (ALVO) Q3 2025 earnings summary", "summary": "Alvotech (ALVO) reported strong Q3 2025 results with $114 million in total revenues, driven by global biosimilar launches, and achieved a profit of $136.5 million for the nine months ended September 30, 2025. The company revised its full-year 2025 revenue guidance to $570\u2013$600 mi", "url": "https://quartr.com/events/alvotech-alvo-q3-2025_F3vPV90A", "source_name": "Quartr", "published_at": "2026-07-10T11:39:17", "published_display": "10 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Alvotech \u2013 NASDAQ:ALVO", "summary": "This article from TradingView focuses on the \"Price to sales forward\" metric for Alvotech (NASDAQ:ALVO). It appears to be a financial data page showing this specific valuation ratio for the company over different periods, presented without additional commentary or detailed analys", "url": "https://www.tradingview.com/symbols/NASDAQ-ALVO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T15:04:45", "published_display": "09 Jul 2026 15:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Alvotech \u2013 NASDAQ:ALVO", "summary": "The article focuses on Alvotech (NASDAQ: ALVO)'s \"Price to book forward\" financial metric. It presents a simple financial data point without further analysis or context. The content is primarily a data placeholder within a financial information platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-ALVO/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T04:39:42", "published_display": "09 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Alvotech \u2013 SWB:Z45", "summary": "This page provides financial data for Alvotech (SWB:Z45) on the Stuttgart Stock Exchange, specifically focusing on its enterprise value to EBIT forward. The content indicates that the market was closed with no trades at the time of viewing. It appears to be a financial data prese", "url": "https://www.tradingview.com/symbols/SWB-Z45/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T21:39:42", "published_display": "08 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech(ALVO) Stock Options Chain | Quotes & News", "summary": "This article provides details on Alvotech (ALVO) stock options, including quotes and recent news. It also includes information about the company's financial overview, insider transactions, price performance, and analyst ratings.", "url": "https://www.moomoo.com/stock/ALVO-US/options-chain?from=share&stockId=202550", "source_name": "Moomoo", "published_at": "2026-07-06T23:09:23", "published_display": "06 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Faces 'Soft' Q2 but Well Positioned to Benefit From Upcoming Biosimilar Opportunity, UBS Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alvotech-faces-apos-soft-apos-192101037.html", "source_name": "MT Newswires", "published_at": "2026-07-06T19:21:01+00:00", "published_display": "06 Jul 2026 19:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (ALVO) Secured $240 Million In New Capital, Is The Stock Cheap?", "summary": "Alvotech (ALVO) recently secured an additional US$240 million in new capital through a credit agreement amendment and earlier equity capital, despite a significant year-to-date share price decline. The company is considered undervalued by Simply Wall St, with a fair value of $13.", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alvo/alvotech/news/alvotech-alvo-secured-240-million-in-new-capital-is-the-stoc", "source_name": "Simply Wall Street", "published_at": "2026-07-05T07:42:01", "published_display": "05 Jul 2026 07:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Warrant 2022-open end on Financial Disclosures & SEC Filings", "summary": "This article provides access to Alvotech's SEC filings and other financial disclosures, including earnings reports and event transcripts from 2024, 2025, and 2026. The documents offer insights into the company's financial performance, operational updates, biosimilar pipeline, gro", "url": "https://www.tradingview.com/symbols/BOATS-ALVOW/documents/", "source_name": "TradingView", "published_at": "2026-07-05T05:42:01", "published_display": "05 Jul 2026 05:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transactions of Managers and Closely Associated Persons", "summary": "Alvotech announced that Celtic Lux Holdings S.a. r.l. pledged 88,940,619 shares and 7,007,321 depository receipts on shares in Alvotech. These transactions occurred on June 26, 2026, and were disclosed via filings with the Luxembourg Commission de Surveillance du Secteur Financie", "url": "https://www.manilatimes.net/2026/07/04/tmt-newswire/globenewswire/transactions-of-managers-and-closely-associated-persons/2378290/amp", "source_name": "The Manila Times", "published_at": "2026-07-04T04:17:00", "published_display": "04 Jul 2026 04:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech further strengthens liquidity by securing term loan facility of $75 million", "summary": "Alvotech has secured an additional $75 million term loan facility from GoldenTree Asset Management and other lenders, further strengthening its financial position. This follows a recent $165 million equity raise, bringing the total new capital accessed to $240 million. The funds ", "url": "https://www.globenewswire.com/news-release/2026/07/01/3320369/0/en/alvotech-further-strengthens-liquidity-by-securing-term-loan-facility-of-75-million.html", "source_name": "GlobeNewswire", "published_at": "2026-07-03T23:39:17", "published_display": "03 Jul 2026 23:39", "sentiment": "positive", "sentiment_pct": 94, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech controller pledges 95.9M shares and depository receipts", "summary": "Alvotech (ALVO) disclosed that Celtic Lux Holdings pledged 88,940,619 shares and 7,007,321 depository receipts, totaling 95.9 million securities, with the Luxembourg CSSF on June 26, 2026. This transaction is classified as a dealing by managers and closely associated persons, pro", "url": "https://www.stocktitan.net/news/ALVO/transactions-of-managers-and-closely-associated-cs1cpyt4qq0b.html", "source_name": "Stock Titan", "published_at": "2026-07-03T20:10:08", "published_display": "03 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Alvotech\u2019s Expanded US$240 Million Capital Access Require Action From Alvotech (ALVO) Investors?", "summary": "Alvotech recently secured an additional US$75 million term loan, bringing its total new capital access to US$240 million, alongside a US$165 million equity raise in June 2026. This financial boost aims to fund its biosimilar pipeline and global expansion, addressing short-term li", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alvo/alvotech/news/should-alvotechs-expanded-us240-million-capital-access-requi", "source_name": "Simply Wall Street", "published_at": "2026-07-02T20:39:09", "published_display": "02 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (ALVO) Stock May Be Undervalued Following Its $125 Million Offering", "summary": "Alvotech (ALVO) stock appears undervalued despite a 64% decline over the past five years, with several valuation tests suggesting it is cheaply priced. The company screens well on valuation metrics according to Simply Wall St, and its P/S ratio of 2.2x is significantly below the ", "url": "https://finance.yahoo.com/markets/stocks/articles/alvotech-alvo-stock-may-undervalued-201122034.html", "source_name": "Market source", "published_at": "2026-07-02T15:11:00", "published_display": "02 Jul 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech\u2019s US$240 Million Capital Boost Might Change The Case For Investing In Alvotech (ALVO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPeHMtMXk5VXVIX2dtdU54VmZGMk1DeWhVd2dwUWl6eU1yM1pickVrcEhqSUV6aVJpa0lieDlZSGFTc290cXRsY2pwNElqcDVQblNvakk4TE1PdF8xaGdOU3pxQkoxYVlUWjJjbjVkM0xPTjFNV3M3WC1oeWhSQ2ZyMklGWFlleGJQRy04dG5yUXhWN1ZIYUE2M2lXSXQ?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Secures Term Loan Facility of $75MM from GoldenTree Asset Management", "summary": "Alvotech secured an additional $75 million term loan facility from GoldenTree Asset Management, further strengthening its financial position after a recent $165 million equity raise. This financing will support the company's growth strategy, including advancing its biosimilar pip", "url": "https://www.abfjournal.com/alvotech-secures-term-loan-facility-of-75mm-from-goldentree-asset-management/", "source_name": "ABF Journal", "published_at": "2026-07-02T06:40:11", "published_display": "02 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (NASDAQ: ALVO) adds $75M term loan, lifting new capital access to $240M", "summary": "Alvotech has secured an additional $75 million term loan facility, led by GoldenTree Asset Management, boosting its total new capital access to $240 million when combined with a recent $165 million equity raise. This financing, bearing a 12.50% interest rate and maturing on Decem", "url": "https://www.stocktitan.net/sec-filings/ALVO/6-k-alvotech-current-report-foreign-issuer-5f33e2f8dbd9.html", "source_name": "Stock Titan", "published_at": "2026-07-01T11:39:21", "published_display": "01 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Obtains $75 Million Term Loan Facility", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alvotech-obtains-75-million-term-083856632.html", "source_name": "MT Newswires", "published_at": "2026-07-01T08:38:56+00:00", "published_display": "01 Jul 2026 08:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Secures Up to $75 Million Additional Term Loan Facility to Support Pipeline and Global Launches", "summary": "Alvotech has secured an additional $75 million term loan facility from GoldenTree Asset Management, bringing its total new capital raised to $240 million, including a recent $165 million equity raise. These funds will be used to advance its research and development pipeline, supp", "url": "https://www.quiverquant.com/news/Alvotech+Secures+Up+to+$75+Million+Additional+Term+Loan+Facility+to+Support+Pipeline+and+Global+Launches", "source_name": "Quiver Quantitative", "published_at": "2026-07-01T08:10:00", "published_display": "01 Jul 2026 08:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech adds $75M debt after $165M equity raise", "summary": "Alvotech (NASDAQ: ALVO) has secured an additional $75 million term loan facility, maturing on December 31, 2027, from GoldenTree Asset Management, bearing a 12.50% interest rate payable monthly in cash. This new debt, combined with a recent $165 million equity raise, provides Alv", "url": "https://www.stocktitan.net/news/ALVO/alvotech-further-strengthens-liquidity-by-securing-term-loan-s12w0q06q9yu.html", "source_name": "Stock Titan", "published_at": "2026-07-01T08:00:10", "published_display": "01 Jul 2026 08:00", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celtic Lux (ALVO) boosts Alvotech holding with $38M PIPE and $40M loan", "summary": "Celtic Holdings S.C.A. and Celtic Lux Holdings S.a r.l. have increased their beneficial ownership in Alvotech to approximately 27.5%, now holding 107,450,988 Ordinary Shares. This boost comes from Celtic Lux's acquisition of 10,133,333 Ordinary Shares for $38 million through a PI", "url": "https://www.stocktitan.net/sec-filings/ALVO/schedule-13d-a-alvotech-amended-major-shareholder-report-072f672e52d3.html", "source_name": "Stock Titan", "published_at": "2026-07-01T00:10:10", "published_display": "01 Jul 2026 00:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Swedish Depository Receipt Repr 1 Sh Actuals & Estimates (TURQUOISE:ALVOS)", "summary": "This article provides an overview of Alvotech Swedish Depository Receipt Repr 1 Sh (TURQUOISE:ALVOS) on TradingView, focusing on its actuals and estimates. It highlights financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valua", "url": "https://www.tradingview.com/symbols/TURQUOISE-ALVOS/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-27T20:09:46", "published_display": "27 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Alvotech \u2013 NASDAQ:ALVOW", "summary": "This article provides current financial information for Alvotech (NASDAQ:ALVOW), specifically focusing on its price-to-book forward ratio. It highlights the company's financial overview on TradingView, listing it under biotechnology stocks in the USA market. The page shows that t", "url": "https://www.tradingview.com/symbols/NASDAQ-ALVOW/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T20:09:46", "published_display": "27 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Alvotech \u2013 NASDAQ:ALVOW", "summary": "The article provides financial information for Alvotech (NASDAQ: ALVOW), specifically focusing on its forward price-to-earnings ratio. It is a data-oriented page that shows a period value for this metric. The content is presented by TradingView, a platform for market data and ana", "url": "https://www.tradingview.com/symbols/NASDAQ-ALVOW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:10:50", "published_display": "27 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech manager filing shows 10.1M shares bought at $3.75", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNYWtFa1h3YU1YTVJFVDNHSW1OcDZhUFFuX202dC1aT3JpT1JMemIwRElDbjJ1ejhmNUtwRUVEREhhN1lGSVU5aExjOHpJci1HendudmFKUTJudmo1T0lmTWJydmxIME9pdXhKbXFVd2dVTUdrV0lYVEV0NUFWaUhyZmp1M214cnFTcWNuelNrN3pVdUluYm80blNaZTJ3LUtQTzVFeA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (ALVO): 10 Penny Stocks With Explosive Growth Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPRlRHSzV0Vk5KcFN2TWdfSXJNWDFCcjAtOHMwTmFwa2E1S28wMWh5Z1ExcnB6Z3Z0ajhqWXhBWUdDNE5wS00xeXF0TllINjdhTUVyWHcwbXZWblRxN09DcFR4SGhDdTNCYm03dUJCTlNsNGNiVHFubHA1TzNzSHJJYng0d1Z3dV9fQlQtX3RlQXZLZ09kUlhTV1dR?oc=5", "source_name": "Market source", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Closes $98 Million Share Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/alvotech-closes-98-million-share-103427444.html", "source_name": "MT Newswires", "published_at": "2026-06-18T10:34:27+00:00", "published_display": "18 Jun 2026 10:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alvotech-announces-closing-public-offering-095100510.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T09:51:00+00:00", "published_display": "18 Jun 2026 09:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech seeks $125M in shares for biosimilar development", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPRVNTOHcwbDRKamhrYVBxT05BUmVIZVZ6V0t0N3EwTDJLNUtoWHhmZnVLMy05TEtWYU1WT0E0cDQtOFdjY2FVWjVIUzZ4U1lqRXdNczMwY1JtWF9obkloc3dWYlZQb1RSem9GZk42VWJfSVBUYVR0YmEzcGx4c3lEaHpkR1h0SGZKMVFmUEhBdEdyYTl5a2VzVjJLT2ZudG5wbmMxTW5QektzUDNBZ0R6RTM4dkk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Alvotech aims to raise up to $165M for biosimilar pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPaVhVOUxPanhrX2dXcUd2dWo4RG5rOGViMkRBX0RQSzl4bU5UR3VteW5jSi11LUdXRXlUbk5mNUthSG5zdzJCYmNOVUNSaVJqZkx0T2s3UlZPZzN3aG0tTjJfdllMbVNSdi04MWIzTUJHNjUxQkhnMzRRbVlRWEZfcFBUaHZ3YS1maWYyZ04wQlZBdHhGdzh2N0ZKMUU2MmRHZ0JkdXpDc25yWGpFSjFvaW92aXJ3UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgJBVV95cUxQUDMzOFgxLTdwMkZ0T2R1UUx4bnVDVVRuS2dLOVRxQUpxTVhMT3o4SVE1dTdlZEd5S0h1OTE4M1V3dlpnbTR0UmtsUDhqb0RZYlZBLWFQYktLODJrZWVmc09NNGhsbHRod3VvMFZsaXp5UlROakh3QVB4bGtzV1ZxXzlURUFFUEFRZnJGWVVmaFMwMzVMUzYyUnRnbV9NUE9md0ptWXlhRmtUQ2J6VW5ZTy1Va1ZKbmNnZTYtckhiTFNfX1kySlp2Ry1kY0U1VHhhQUJtWXFfVjBLa3ptSVhsNDRiVVUzUjlQV1N3b0szcDRpNHNVNlFvOU15ZlFDU0NNYlMwM0NFVXcwZy1nMXc?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech seeks $125M to fund biosimilar medicines via share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPNG1pd0ZjMGFJRVVPdkUybFBCT2RoVmF1UFliOWFTWHZIeWlJN1VKbkZVRk43LXQwem82aUpjai1lVkZIZTUxdVFkLTRaTWNjS3RjT0NFZVlZUVhEbFpldEZsTnFRMlFMekhyaUJjOExSbVVKVVc1WE1GUnJyRE9JMS1TZDJXZzM1aVdLOWFqMW1QSWktZkhvd1NsZFlpWHZ6b0R5UDZtaXQ0ZlFkZU9WbVRSQmo?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (ALVO) Returns To Quarterly Profitability Challenging Concern Over Persistent Losses", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech gains on FDA acceptance of Entyvio biosimilar BLA (ALVO:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOQ2sxeVljcWQ2bTYteEdqTzBCNHFXbTd3UzZPZEtkeGcyRGk2dFFSMjJhaDYyeF9lX1RXSEpITTZfc0hNQzNpblloX3FJVjd5Mi03NGI0RDNLY3k3U1psdkIyR0l1ZlRaSTZvRnFZUWFxRHhEMW11S29WZ0l1SjExLVJJQmNDT2JQdXRYM29xNDR2UDVuZzJzRVM5N20?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech shares jump after FDA accepts Entyvio biosimilar application for review (ALVO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQTlFEYXNOeTlCeWEzVzVOWmtVdUk2c2tkNDVTeGxBLWszcWJ2OXlpZXRXMzhnbWtjdG9jNVJ2QlVYNU81WE5talRBMTV1S2RJMGh5Wk9mRW5hMmlJWVliLVNCczF4WTNjSFRoWGQwTkFHcjBfQUlGRFBVX1U4c014bkNSSzRYRG9VRmg5S1BIVERjWWFFUEY5UlBFdm5nRFlkcjlr?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQMXhTN1UydTctR3Nsc2t2SS1scGYyUGtQOTBuLUFwNkpDMlRqMmxabkhyam0tU3ROcmd3RDJWeEVvTTRuWkRkeWE3R2tBVFoteGFrWWxLYVlDekJiU1RiRHVURnlVMk94ZWhmTkxtbXRkaFprbVFnaU1aUUtsUm13U3V6NXJhNUJOWlhhS2UxRHhZYjJES3dRMklaTE55WjlEZjR4SQ?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Alvotech joins Jefferies, Goldman Sachs, UBS investor talks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOWnpNQ0Jtajh5SzdnLUl2Y2Z5aFY2UkFTRXJyYnhrenJxS2Zqam91eDJfYlVVaDZCaG1PckpEQ0Vtd2E1bDZwVnUwLXNESDVpOGZRWlpkREZ5VG5ib3UyTkRNNm95UzBhSld2WDlRelU0SW1nYTQ3X2M2RTR0OFZ5VWhKX2dMel9BZS1obERlOXozR0ZRVjUyeGhTNEQ5SkppRXI4NkVRbTh0WEg4UVFN?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech and Islandsbanki Renew Market Making Agreement to Enhance Share Liquidity on Nasdaq Iceland", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPazR2TktQUW1saGI1NWZJakVDSWJNVHNPRTJ6c04yeEhBZjJYTlJCU2tuQk92c3FHTjN1VGs2UjlkLWcyYl9LYnl4V1VkazBaXzNJU2gwSVB4Z1MxczNJeHRwX1ViY3pOWGVBMlJvbENza1pnRS1Vd3QxeGtzcEl1SlpTcmtQanlXTklGdWVLSWl2NDNEX1JGYWdxX0xPSXFfV2VXZndhc1d0VUJzWXlVM0U5anlkckpKQ2N4VThMRWZySFlQRjUzeGdULXdQUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNUnd5ckhnTXJNQllvWWM5TXlaQ3NIWkpEX0FWeUVMWTNCTWhXSkRULWlaSTRsRjFHN09pQlFURUZqdTBOTDNib0pFUUhxX1lXZjEzWjJYd2U4Z0NaVlhCZWU3VnhpOXRGQUZSLWFjR2lORHVFbVA2cVhXZjlaWFJ5bGMyU3hqcUFPS1M2OE1zQjhCRndr?oc=5", "source_name": "MarketBeat", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOaFhybERQUTgtcmJXVTdxdVFyNE1zYUdnQVRaZE5Fd28xTkNsRF9mZzV2M0ljUG1JNXZYNXZMRzNjdlc5Q2V3enRzQ2Z1MlA3UHlLcnpwX3BZR3EwM1JoYXk4MGEyZG1pcGZXcy1uTWhpWURTczVjdWUxa1phM3RXaGgxT3Q0Z2hpc2NlNDBPSF80NjVzYzJxVGh3?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (NASDAQ:ALVO) Q1 2026 Results Miss Estimates, Shares Drop Over 9% as Revenue and EPS Fall Short", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxONURwcmhwVm1DcWEtQ2FqcXVhRHZvakRMZVNQQ1MzaG1RNjd4aTF6T0NUdXM5WC1hM00tSHBnWDJ1dUQwUzZLdkUwTGNYR0dHS1NlcXN2dlEya0FIMGJtaWF0MU9xWmFyRnBCMkx1anFSOGN3aFF6NUtXSzhFZ2dLd2dwR19XWmxabVJRZzF5RGRTMkRsdjAtWlY5em1nRUdaaWdyTjVtNnNOZWdfcTVRZWtxcWRGbkZYQnNWLTJwcG1QeHY3bG5jMnNDZ0lGRWRhaG1lYnFmVmF3U1JHNXV1NFhOOEFTZw?oc=5", "source_name": "ChartMill", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (ALVO) Valuation Gap Under Review After Mixed Share Performance And Biosimilar Pipeline Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOd1pvSnVwVUM2c294NFloODVNZ09UMHp1RUpSOXJiODRRTHVQRW9CSm1lcEhuZDhzamVUc0t0LUVSQlZpRnRlSGxpSDdaLXhOYzlTd0ZRUmR4T3ZKcVdrRjBKUGttTFhqeXJKaHlDWHhNazlCQ1pJSll1cE1VZ1VucDFkcW5sS3pCRjJHUXVWWlp5ck1iNXRZSmlSVnNaenc?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s What the Street Thinks About Alvotech (ALVO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQdEVYRHY5ajVKRGVDV2tGdzh4TkExWTZKblh5cGlfNTRrYW9ZNkZ0eEVVSU03M0xHZzIwSUQ2RnFXZE9ZSzhmNmZSVksyUTEwSXZUMVRBWWoyOTFkaDdsZllGOWFUT3dPbUZ1dlFvbWpoQzFpZWZxcG1vX1k0dmdUV2IwajJvUHN5anRUUi15LThGLU1oTHEw?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech: Improving Fundamentals Signal Potential Bottom For This Biosimilar Player (ALVO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOVVBRbUFpZlZJWnpUMV9HbUl1bUo4cUJ2M1BUY2Ria2d6VXpGMVJrZU1PZDUzQ2drOXZKU2JrNUpNWVVjZ2dDRU0zU2d2SHdiaTlvaUJKMjFncE9ZR2hxNkczcHNTcWdoMWNNODNLeGZKZXRoQk05YjE2SEp1QW1ESWtMa0xBSS1ndHNIelpISGtDM2ZjS3NXVkl2TUYwbVF3MjV0cWRrZUxRYmxJWFJHeXU0Z05xS0JXSEMxYUxFeWZvcUU?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is There Now an Opportunity in Alvotech (ALVO) After a 64% One-Year Share Price Slide?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Alvotech (ALVO) Pricing Make Sense After A 64% One Year Share Price Slump", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxOV1dMYXdlM1pYWm4tVFRsSEsydG1oTWdXMTJqd3ppY1BsVGprdHFESk1WdmE5MXZORzlEVUotSjBjeWhTUHBWMF9pR3dhRTlOc05fbUcyaWZ6RDJoTEF4dmxQcDBoMlZHV0w5UjEwcEVyQ29JbWNVZjhtRGc0aW1adkJB?oc=5", "source_name": "Market source", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Increases Share Capital by $125,000 Through Issuance of 12.5 Million Ordinary Shares | ALVO Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOX3dYU3ZiTlBRM1BvSmVodThzbGFuWWFtZEJ6NHg1RjVpZTFVZ1kwOGtXUjJLTklWa25VNkh0OU1aQjY0ZTZpZlVKY0k0X1UxVEpqZ2xnM2h6VW5QSzI1Q0xwMVJVeVQtVS15SFdBR3FXMmVhRFRJWHE0WWwyanRVS0NRTmRHOTlUTzVpWnpwSUxfXzhvYUJoTzZNY2JJMmdTaGhRZXFwb2xXS2p4cXV5UDZRbUlDTi1rWU91c3RfQWhMUmE4djZ0TVRB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea\u00ae", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPQXZHSk92amFQajJVUS1OR0ZOVkdDMjZPRXlJbFBBZm53c0NEVHZBM2VpV0ZRdWpnMWhaUWRUWjlxQnZuUEZUOGw3aldYZFhKbkwweXlzb3h0anNnbFNfbk9CaWxTMFNVWmZ3SHdwOFVRTXVRQnNuWUFGck9iTTF2cVMwUGdTZw?oc=5", "source_name": "Market source", "published_at": "2025-12-19T08:00:00+00:00", "published_display": "19 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech's (NASDAQ:ALVO) 31% Dip In Price Shows Sentiment Is Matching Revenues", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-09T08:00:00+00:00", "published_display": "09 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPWWlQX0dpWnBucExoSXl1THp6MDFjWHZTZmZHZ29PbUNHVE5wQ1d5bzZvU0paMUxxMm1kUnJUTXJHdk81ME9xNUZBQnB2cmtyYlFaWEdRSzAycWV4N3VmaFBrZXp0aldzWFQ0NHpMY2NFM1l5T1VjRkdqMUc5SGNsQnpnMA?oc=5", "source_name": "Market source", "published_at": "2025-09-23T07:00:00+00:00", "published_display": "23 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "ALVO Stock Price Prediction 2025-2026 | Alvotech Forecast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE5wOWRJSkhhdF95ck1DR3NrcmFDV2ZiUDFjWVVuTjZxYVB1RllDZC1oR2FFajNDZWJudVhjYll6akhXVk96cHU1X2VoMkhnTkxRWHJ1alVhNUxfN2N4cVdsZkMzUzY?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-07-15T15:07:47+00:00", "published_display": "15 Jul 2026 15:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (ALVO) Could Be 76% Below Fair Value On New $75 Million Debt Facility", "summary": "Alvotech (ALVO) has recently secured a new $75 million debt facility and raised $165 million in equity, providing $240 million for its biosimilar pipeline and commercialization. Despite this new capital, the company's stock has faced significant pressure, falling over 60% in the ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alvo/alvotech/news/alvotech-alvo-could-be-76-below-fair-value-on-new-75-million", "source_name": "Simply Wall Street", "published_at": "2026-07-15T09:13:18", "published_display": "15 Jul 2026 09:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (NASDAQ:ALVO) Shares Down 5.5% - Here's What Happened", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPWnlkaWwyYmYtOVlTNkhTbFJITzNyUGo3RWZIa2NNc05ydmw0Q3k0a0ktSU5QTEs0MTJEVE9IeFd4NDVhYzgxMjZEMWJsekZFeUxOWUcwSDF0bXBiekhhVFpiSXVCS20xNXNnVHMxMDlKeWVlQ1RlX2x6WDAwNDd4bXZnTy1JazVhQ2IwLXJORjVOZUZsSklDdDFob0hvMXNhWk1BbXVhRDR3T1FE?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-14T17:49:55+00:00", "published_display": "14 Jul 2026 17:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (ALVO) Barclays 27th Annual Global Healthcare Conference 2025 Summary", "summary": "This article summarizes Alvotech's presentation at the Barclays 27th Annual Global Healthcare Conference 2025, highlighting its focus on biosimilars, global reach, and financial projections. Key points include an expected 2025 revenue of $600\u2013$800 million, strong performance of i", "url": "https://quartr.com/events/alvotech-alvo-barclays-27th-annual-global-healthcare-conference-2025_F3vP6ngK", "source_name": "Quartr", "published_at": "2026-07-13T17:11:30", "published_display": "13 Jul 2026 17:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Alvotech Stocks", "summary": "This article lists various ETFs that hold shares of Alvotech (ALVO), a biotechnology company. It provides details such as the market value of Alvotech stocks within each ETF, their weight, issuer, management style, expense ratio, and assets under management. The information aims ", "url": "https://www.tradingview.com/symbols/OMXICE-ALVO/etfs/", "source_name": "TradingView", "published_at": "2026-07-12T21:10:42", "published_display": "12 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Alvotech \u2013 NASDAQ:ALVO", "summary": "This page provides financial information for Alvotech (NASDAQ: ALVO), specifically focusing on its enterprise value to EBITDA forward metric. It indicates that the market was closed at the time of the data display. The page is part of TradingView's financial analysis tools, offer", "url": "https://www.tradingview.com/symbols/NASDAQ-ALVO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T12:39:17", "published_display": "10 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (ALVO) Q3 2025 earnings summary", "summary": "Alvotech (ALVO) reported strong Q3 2025 results with $114 million in total revenues, driven by global biosimilar launches, and achieved a profit of $136.5 million for the nine months ended September 30, 2025. The company revised its full-year 2025 revenue guidance to $570\u2013$600 mi", "url": "https://quartr.com/events/alvotech-alvo-q3-2025_F3vPV90A", "source_name": "Quartr", "published_at": "2026-07-10T11:39:17", "published_display": "10 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Alvotech \u2013 NASDAQ:ALVO", "summary": "This article from TradingView focuses on the \"Price to sales forward\" metric for Alvotech (NASDAQ:ALVO). It appears to be a financial data page showing this specific valuation ratio for the company over different periods, presented without additional commentary or detailed analys", "url": "https://www.tradingview.com/symbols/NASDAQ-ALVO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T15:04:45", "published_display": "09 Jul 2026 15:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Alvotech \u2013 NASDAQ:ALVO", "summary": "The article focuses on Alvotech (NASDAQ: ALVO)'s \"Price to book forward\" financial metric. It presents a simple financial data point without further analysis or context. The content is primarily a data placeholder within a financial information platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-ALVO/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T04:39:42", "published_display": "09 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Alvotech \u2013 SWB:Z45", "summary": "This page provides financial data for Alvotech (SWB:Z45) on the Stuttgart Stock Exchange, specifically focusing on its enterprise value to EBIT forward. The content indicates that the market was closed with no trades at the time of viewing. It appears to be a financial data prese", "url": "https://www.tradingview.com/symbols/SWB-Z45/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T21:39:42", "published_display": "08 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech(ALVO) Stock Options Chain | Quotes & News", "summary": "This article provides details on Alvotech (ALVO) stock options, including quotes and recent news. It also includes information about the company's financial overview, insider transactions, price performance, and analyst ratings.", "url": "https://www.moomoo.com/stock/ALVO-US/options-chain?from=share&stockId=202550", "source_name": "Moomoo", "published_at": "2026-07-06T23:09:23", "published_display": "06 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Faces 'Soft' Q2 but Well Positioned to Benefit From Upcoming Biosimilar Opportunity, UBS Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alvotech-faces-apos-soft-apos-192101037.html", "source_name": "MT Newswires", "published_at": "2026-07-06T19:21:01+00:00", "published_display": "06 Jul 2026 19:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (ALVO) Secured $240 Million In New Capital, Is The Stock Cheap?", "summary": "Alvotech (ALVO) recently secured an additional US$240 million in new capital through a credit agreement amendment and earlier equity capital, despite a significant year-to-date share price decline. The company is considered undervalued by Simply Wall St, with a fair value of $13.", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alvo/alvotech/news/alvotech-alvo-secured-240-million-in-new-capital-is-the-stoc", "source_name": "Simply Wall Street", "published_at": "2026-07-05T07:42:01", "published_display": "05 Jul 2026 07:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Warrant 2022-open end on Financial Disclosures & SEC Filings", "summary": "This article provides access to Alvotech's SEC filings and other financial disclosures, including earnings reports and event transcripts from 2024, 2025, and 2026. The documents offer insights into the company's financial performance, operational updates, biosimilar pipeline, gro", "url": "https://www.tradingview.com/symbols/BOATS-ALVOW/documents/", "source_name": "TradingView", "published_at": "2026-07-05T05:42:01", "published_display": "05 Jul 2026 05:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transactions of Managers and Closely Associated Persons", "summary": "Alvotech announced that Celtic Lux Holdings S.a. r.l. pledged 88,940,619 shares and 7,007,321 depository receipts on shares in Alvotech. These transactions occurred on June 26, 2026, and were disclosed via filings with the Luxembourg Commission de Surveillance du Secteur Financie", "url": "https://www.manilatimes.net/2026/07/04/tmt-newswire/globenewswire/transactions-of-managers-and-closely-associated-persons/2378290/amp", "source_name": "The Manila Times", "published_at": "2026-07-04T04:17:00", "published_display": "04 Jul 2026 04:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech further strengthens liquidity by securing term loan facility of $75 million", "summary": "Alvotech has secured an additional $75 million term loan facility from GoldenTree Asset Management and other lenders, further strengthening its financial position. This follows a recent $165 million equity raise, bringing the total new capital accessed to $240 million. The funds ", "url": "https://www.globenewswire.com/news-release/2026/07/01/3320369/0/en/alvotech-further-strengthens-liquidity-by-securing-term-loan-facility-of-75-million.html", "source_name": "GlobeNewswire", "published_at": "2026-07-03T23:39:17", "published_display": "03 Jul 2026 23:39", "sentiment": "positive", "sentiment_pct": 94, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech controller pledges 95.9M shares and depository receipts", "summary": "Alvotech (ALVO) disclosed that Celtic Lux Holdings pledged 88,940,619 shares and 7,007,321 depository receipts, totaling 95.9 million securities, with the Luxembourg CSSF on June 26, 2026. This transaction is classified as a dealing by managers and closely associated persons, pro", "url": "https://www.stocktitan.net/news/ALVO/transactions-of-managers-and-closely-associated-cs1cpyt4qq0b.html", "source_name": "Stock Titan", "published_at": "2026-07-03T20:10:08", "published_display": "03 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Alvotech\u2019s Expanded US$240 Million Capital Access Require Action From Alvotech (ALVO) Investors?", "summary": "Alvotech recently secured an additional US$75 million term loan, bringing its total new capital access to US$240 million, alongside a US$165 million equity raise in June 2026. This financial boost aims to fund its biosimilar pipeline and global expansion, addressing short-term li", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alvo/alvotech/news/should-alvotechs-expanded-us240-million-capital-access-requi", "source_name": "Simply Wall Street", "published_at": "2026-07-02T20:39:09", "published_display": "02 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (ALVO) Stock May Be Undervalued Following Its $125 Million Offering", "summary": "Alvotech (ALVO) stock appears undervalued despite a 64% decline over the past five years, with several valuation tests suggesting it is cheaply priced. The company screens well on valuation metrics according to Simply Wall St, and its P/S ratio of 2.2x is significantly below the ", "url": "https://finance.yahoo.com/markets/stocks/articles/alvotech-alvo-stock-may-undervalued-201122034.html", "source_name": "Market source", "published_at": "2026-07-02T15:11:00", "published_display": "02 Jul 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech\u2019s US$240 Million Capital Boost Might Change The Case For Investing In Alvotech (ALVO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPeHMtMXk5VXVIX2dtdU54VmZGMk1DeWhVd2dwUWl6eU1yM1pickVrcEhqSUV6aVJpa0lieDlZSGFTc290cXRsY2pwNElqcDVQblNvakk4TE1PdF8xaGdOU3pxQkoxYVlUWjJjbjVkM0xPTjFNV3M3WC1oeWhSQ2ZyMklGWFlleGJQRy04dG5yUXhWN1ZIYUE2M2lXSXQ?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Secures Term Loan Facility of $75MM from GoldenTree Asset Management", "summary": "Alvotech secured an additional $75 million term loan facility from GoldenTree Asset Management, further strengthening its financial position after a recent $165 million equity raise. This financing will support the company's growth strategy, including advancing its biosimilar pip", "url": "https://www.abfjournal.com/alvotech-secures-term-loan-facility-of-75mm-from-goldentree-asset-management/", "source_name": "ABF Journal", "published_at": "2026-07-02T06:40:11", "published_display": "02 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (NASDAQ: ALVO) adds $75M term loan, lifting new capital access to $240M", "summary": "Alvotech has secured an additional $75 million term loan facility, led by GoldenTree Asset Management, boosting its total new capital access to $240 million when combined with a recent $165 million equity raise. This financing, bearing a 12.50% interest rate and maturing on Decem", "url": "https://www.stocktitan.net/sec-filings/ALVO/6-k-alvotech-current-report-foreign-issuer-5f33e2f8dbd9.html", "source_name": "Stock Titan", "published_at": "2026-07-01T11:39:21", "published_display": "01 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Obtains $75 Million Term Loan Facility", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alvotech-obtains-75-million-term-083856632.html", "source_name": "MT Newswires", "published_at": "2026-07-01T08:38:56+00:00", "published_display": "01 Jul 2026 08:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Secures Up to $75 Million Additional Term Loan Facility to Support Pipeline and Global Launches", "summary": "Alvotech has secured an additional $75 million term loan facility from GoldenTree Asset Management, bringing its total new capital raised to $240 million, including a recent $165 million equity raise. These funds will be used to advance its research and development pipeline, supp", "url": "https://www.quiverquant.com/news/Alvotech+Secures+Up+to+$75+Million+Additional+Term+Loan+Facility+to+Support+Pipeline+and+Global+Launches", "source_name": "Quiver Quantitative", "published_at": "2026-07-01T08:10:00", "published_display": "01 Jul 2026 08:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech adds $75M debt after $165M equity raise", "summary": "Alvotech (NASDAQ: ALVO) has secured an additional $75 million term loan facility, maturing on December 31, 2027, from GoldenTree Asset Management, bearing a 12.50% interest rate payable monthly in cash. This new debt, combined with a recent $165 million equity raise, provides Alv", "url": "https://www.stocktitan.net/news/ALVO/alvotech-further-strengthens-liquidity-by-securing-term-loan-s12w0q06q9yu.html", "source_name": "Stock Titan", "published_at": "2026-07-01T08:00:10", "published_display": "01 Jul 2026 08:00", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celtic Lux (ALVO) boosts Alvotech holding with $38M PIPE and $40M loan", "summary": "Celtic Holdings S.C.A. and Celtic Lux Holdings S.a r.l. have increased their beneficial ownership in Alvotech to approximately 27.5%, now holding 107,450,988 Ordinary Shares. This boost comes from Celtic Lux's acquisition of 10,133,333 Ordinary Shares for $38 million through a PI", "url": "https://www.stocktitan.net/sec-filings/ALVO/schedule-13d-a-alvotech-amended-major-shareholder-report-072f672e52d3.html", "source_name": "Stock Titan", "published_at": "2026-07-01T00:10:10", "published_display": "01 Jul 2026 00:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Swedish Depository Receipt Repr 1 Sh Actuals & Estimates (TURQUOISE:ALVOS)", "summary": "This article provides an overview of Alvotech Swedish Depository Receipt Repr 1 Sh (TURQUOISE:ALVOS) on TradingView, focusing on its actuals and estimates. It highlights financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valua", "url": "https://www.tradingview.com/symbols/TURQUOISE-ALVOS/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-27T20:09:46", "published_display": "27 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Alvotech \u2013 NASDAQ:ALVOW", "summary": "This article provides current financial information for Alvotech (NASDAQ:ALVOW), specifically focusing on its price-to-book forward ratio. It highlights the company's financial overview on TradingView, listing it under biotechnology stocks in the USA market. The page shows that t", "url": "https://www.tradingview.com/symbols/NASDAQ-ALVOW/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T20:09:46", "published_display": "27 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Alvotech \u2013 NASDAQ:ALVOW", "summary": "The article provides financial information for Alvotech (NASDAQ: ALVOW), specifically focusing on its forward price-to-earnings ratio. It is a data-oriented page that shows a period value for this metric. The content is presented by TradingView, a platform for market data and ana", "url": "https://www.tradingview.com/symbols/NASDAQ-ALVOW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:10:50", "published_display": "27 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech manager filing shows 10.1M shares bought at $3.75", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNYWtFa1h3YU1YTVJFVDNHSW1OcDZhUFFuX202dC1aT3JpT1JMemIwRElDbjJ1ejhmNUtwRUVEREhhN1lGSVU5aExjOHpJci1HendudmFKUTJudmo1T0lmTWJydmxIME9pdXhKbXFVd2dVTUdrV0lYVEV0NUFWaUhyZmp1M214cnFTcWNuelNrN3pVdUluYm80blNaZTJ3LUtQTzVFeA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (ALVO): 10 Penny Stocks With Explosive Growth Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPRlRHSzV0Vk5KcFN2TWdfSXJNWDFCcjAtOHMwTmFwa2E1S28wMWh5Z1ExcnB6Z3Z0ajhqWXhBWUdDNE5wS00xeXF0TllINjdhTUVyWHcwbXZWblRxN09DcFR4SGhDdTNCYm03dUJCTlNsNGNiVHFubHA1TzNzSHJJYng0d1Z3dV9fQlQtX3RlQXZLZ09kUlhTV1dR?oc=5", "source_name": "Market source", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Closes $98 Million Share Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/alvotech-closes-98-million-share-103427444.html", "source_name": "MT Newswires", "published_at": "2026-06-18T10:34:27+00:00", "published_display": "18 Jun 2026 10:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alvotech-announces-closing-public-offering-095100510.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T09:51:00+00:00", "published_display": "18 Jun 2026 09:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech seeks $125M in shares for biosimilar development", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPRVNTOHcwbDRKamhrYVBxT05BUmVIZVZ6V0t0N3EwTDJLNUtoWHhmZnVLMy05TEtWYU1WT0E0cDQtOFdjY2FVWjVIUzZ4U1lqRXdNczMwY1JtWF9obkloc3dWYlZQb1RSem9GZk42VWJfSVBUYVR0YmEzcGx4c3lEaHpkR1h0SGZKMVFmUEhBdEdyYTl5a2VzVjJLT2ZudG5wbmMxTW5QektzUDNBZ0R6RTM4dkk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Alvotech aims to raise up to $165M for biosimilar pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPaVhVOUxPanhrX2dXcUd2dWo4RG5rOGViMkRBX0RQSzl4bU5UR3VteW5jSi11LUdXRXlUbk5mNUthSG5zdzJCYmNOVUNSaVJqZkx0T2s3UlZPZzN3aG0tTjJfdllMbVNSdi04MWIzTUJHNjUxQkhnMzRRbVlRWEZfcFBUaHZ3YS1maWYyZ04wQlZBdHhGdzh2N0ZKMUU2MmRHZ0JkdXpDc25yWGpFSjFvaW92aXJ3UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgJBVV95cUxQUDMzOFgxLTdwMkZ0T2R1UUx4bnVDVVRuS2dLOVRxQUpxTVhMT3o4SVE1dTdlZEd5S0h1OTE4M1V3dlpnbTR0UmtsUDhqb0RZYlZBLWFQYktLODJrZWVmc09NNGhsbHRod3VvMFZsaXp5UlROakh3QVB4bGtzV1ZxXzlURUFFUEFRZnJGWVVmaFMwMzVMUzYyUnRnbV9NUE9md0ptWXlhRmtUQ2J6VW5ZTy1Va1ZKbmNnZTYtckhiTFNfX1kySlp2Ry1kY0U1VHhhQUJtWXFfVjBLa3ptSVhsNDRiVVUzUjlQV1N3b0szcDRpNHNVNlFvOU15ZlFDU0NNYlMwM0NFVXcwZy1nMXc?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech seeks $125M to fund biosimilar medicines via share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPNG1pd0ZjMGFJRVVPdkUybFBCT2RoVmF1UFliOWFTWHZIeWlJN1VKbkZVRk43LXQwem82aUpjai1lVkZIZTUxdVFkLTRaTWNjS3RjT0NFZVlZUVhEbFpldEZsTnFRMlFMekhyaUJjOExSbVVKVVc1WE1GUnJyRE9JMS1TZDJXZzM1aVdLOWFqMW1QSWktZkhvd1NsZFlpWHZ6b0R5UDZtaXQ0ZlFkZU9WbVRSQmo?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (ALVO) Returns To Quarterly Profitability Challenging Concern Over Persistent Losses", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech gains on FDA acceptance of Entyvio biosimilar BLA (ALVO:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOQ2sxeVljcWQ2bTYteEdqTzBCNHFXbTd3UzZPZEtkeGcyRGk2dFFSMjJhaDYyeF9lX1RXSEpITTZfc0hNQzNpblloX3FJVjd5Mi03NGI0RDNLY3k3U1psdkIyR0l1ZlRaSTZvRnFZUWFxRHhEMW11S29WZ0l1SjExLVJJQmNDT2JQdXRYM29xNDR2UDVuZzJzRVM5N20?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech shares jump after FDA accepts Entyvio biosimilar application for review (ALVO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQTlFEYXNOeTlCeWEzVzVOWmtVdUk2c2tkNDVTeGxBLWszcWJ2OXlpZXRXMzhnbWtjdG9jNVJ2QlVYNU81WE5talRBMTV1S2RJMGh5Wk9mRW5hMmlJWVliLVNCczF4WTNjSFRoWGQwTkFHcjBfQUlGRFBVX1U4c014bkNSSzRYRG9VRmg5S1BIVERjWWFFUEY5UlBFdm5nRFlkcjlr?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQMXhTN1UydTctR3Nsc2t2SS1scGYyUGtQOTBuLUFwNkpDMlRqMmxabkhyam0tU3ROcmd3RDJWeEVvTTRuWkRkeWE3R2tBVFoteGFrWWxLYVlDekJiU1RiRHVURnlVMk94ZWhmTkxtbXRkaFprbVFnaU1aUUtsUm13U3V6NXJhNUJOWlhhS2UxRHhZYjJES3dRMklaTE55WjlEZjR4SQ?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Alvotech joins Jefferies, Goldman Sachs, UBS investor talks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOWnpNQ0Jtajh5SzdnLUl2Y2Z5aFY2UkFTRXJyYnhrenJxS2Zqam91eDJfYlVVaDZCaG1PckpEQ0Vtd2E1bDZwVnUwLXNESDVpOGZRWlpkREZ5VG5ib3UyTkRNNm95UzBhSld2WDlRelU0SW1nYTQ3X2M2RTR0OFZ5VWhKX2dMel9BZS1obERlOXozR0ZRVjUyeGhTNEQ5SkppRXI4NkVRbTh0WEg4UVFN?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech and Islandsbanki Renew Market Making Agreement to Enhance Share Liquidity on Nasdaq Iceland", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPazR2TktQUW1saGI1NWZJakVDSWJNVHNPRTJ6c04yeEhBZjJYTlJCU2tuQk92c3FHTjN1VGs2UjlkLWcyYl9LYnl4V1VkazBaXzNJU2gwSVB4Z1MxczNJeHRwX1ViY3pOWGVBMlJvbENza1pnRS1Vd3QxeGtzcEl1SlpTcmtQanlXTklGdWVLSWl2NDNEX1JGYWdxX0xPSXFfV2VXZndhc1d0VUJzWXlVM0U5anlkckpKQ2N4VThMRWZySFlQRjUzeGdULXdQUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNUnd5ckhnTXJNQllvWWM5TXlaQ3NIWkpEX0FWeUVMWTNCTWhXSkRULWlaSTRsRjFHN09pQlFURUZqdTBOTDNib0pFUUhxX1lXZjEzWjJYd2U4Z0NaVlhCZWU3VnhpOXRGQUZSLWFjR2lORHVFbVA2cVhXZjlaWFJ5bGMyU3hqcUFPS1M2OE1zQjhCRndr?oc=5", "source_name": "MarketBeat", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOaFhybERQUTgtcmJXVTdxdVFyNE1zYUdnQVRaZE5Fd28xTkNsRF9mZzV2M0ljUG1JNXZYNXZMRzNjdlc5Q2V3enRzQ2Z1MlA3UHlLcnpwX3BZR3EwM1JoYXk4MGEyZG1pcGZXcy1uTWhpWURTczVjdWUxa1phM3RXaGgxT3Q0Z2hpc2NlNDBPSF80NjVzYzJxVGh3?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (NASDAQ:ALVO) Q1 2026 Results Miss Estimates, Shares Drop Over 9% as Revenue and EPS Fall Short", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxONURwcmhwVm1DcWEtQ2FqcXVhRHZvakRMZVNQQ1MzaG1RNjd4aTF6T0NUdXM5WC1hM00tSHBnWDJ1dUQwUzZLdkUwTGNYR0dHS1NlcXN2dlEya0FIMGJtaWF0MU9xWmFyRnBCMkx1anFSOGN3aFF6NUtXSzhFZ2dLd2dwR19XWmxabVJRZzF5RGRTMkRsdjAtWlY5em1nRUdaaWdyTjVtNnNOZWdfcTVRZWtxcWRGbkZYQnNWLTJwcG1QeHY3bG5jMnNDZ0lGRWRhaG1lYnFmVmF3U1JHNXV1NFhOOEFTZw?oc=5", "source_name": "ChartMill", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech (ALVO) Valuation Gap Under Review After Mixed Share Performance And Biosimilar Pipeline Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOd1pvSnVwVUM2c294NFloODVNZ09UMHp1RUpSOXJiODRRTHVQRW9CSm1lcEhuZDhzamVUc0t0LUVSQlZpRnRlSGxpSDdaLXhOYzlTd0ZRUmR4T3ZKcVdrRjBKUGttTFhqeXJKaHlDWHhNazlCQ1pJSll1cE1VZ1VucDFkcW5sS3pCRjJHUXVWWlp5ck1iNXRZSmlSVnNaenc?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s What the Street Thinks About Alvotech (ALVO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQdEVYRHY5ajVKRGVDV2tGdzh4TkExWTZKblh5cGlfNTRrYW9ZNkZ0eEVVSU03M0xHZzIwSUQ2RnFXZE9ZSzhmNmZSVksyUTEwSXZUMVRBWWoyOTFkaDdsZllGOWFUT3dPbUZ1dlFvbWpoQzFpZWZxcG1vX1k0dmdUV2IwajJvUHN5anRUUi15LThGLU1oTHEw?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech: Improving Fundamentals Signal Potential Bottom For This Biosimilar Player (ALVO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOVVBRbUFpZlZJWnpUMV9HbUl1bUo4cUJ2M1BUY2Ria2d6VXpGMVJrZU1PZDUzQ2drOXZKU2JrNUpNWVVjZ2dDRU0zU2d2SHdiaTlvaUJKMjFncE9ZR2hxNkczcHNTcWdoMWNNODNLeGZKZXRoQk05YjE2SEp1QW1ESWtMa0xBSS1ndHNIelpISGtDM2ZjS3NXVkl2TUYwbVF3MjV0cWRrZUxRYmxJWFJHeXU0Z05xS0JXSEMxYUxFeWZvcUU?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is There Now an Opportunity in Alvotech (ALVO) After a 64% One-Year Share Price Slide?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Alvotech (ALVO) Pricing Make Sense After A 64% One Year Share Price Slump", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxOV1dMYXdlM1pYWm4tVFRsSEsydG1oTWdXMTJqd3ppY1BsVGprdHFESk1WdmE5MXZORzlEVUotSjBjeWhTUHBWMF9pR3dhRTlOc05fbUcyaWZ6RDJoTEF4dmxQcDBoMlZHV0w5UjEwcEVyQ29JbWNVZjhtRGc0aW1adkJB?oc=5", "source_name": "Market source", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech Increases Share Capital by $125,000 Through Issuance of 12.5 Million Ordinary Shares | ALVO Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOX3dYU3ZiTlBRM1BvSmVodThzbGFuWWFtZEJ6NHg1RjVpZTFVZ1kwOGtXUjJLTklWa25VNkh0OU1aQjY0ZTZpZlVKY0k0X1UxVEpqZ2xnM2h6VW5QSzI1Q0xwMVJVeVQtVS15SFdBR3FXMmVhRFRJWHE0WWwyanRVS0NRTmRHOTlUTzVpWnpwSUxfXzhvYUJoTzZNY2JJMmdTaGhRZXFwb2xXS2p4cXV5UDZRbUlDTi1rWU91c3RfQWhMUmE4djZ0TVRB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea\u00ae", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPQXZHSk92amFQajJVUS1OR0ZOVkdDMjZPRXlJbFBBZm53c0NEVHZBM2VpV0ZRdWpnMWhaUWRUWjlxQnZuUEZUOGw3aldYZFhKbkwweXlzb3h0anNnbFNfbk9CaWxTMFNVWmZ3SHdwOFVRTXVRQnNuWUFGck9iTTF2cVMwUGdTZw?oc=5", "source_name": "Market source", "published_at": "2025-12-19T08:00:00+00:00", "published_display": "19 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech's (NASDAQ:ALVO) 31% Dip In Price Shows Sentiment Is Matching Revenues", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-09T08:00:00+00:00", "published_display": "09 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPWWlQX0dpWnBucExoSXl1THp6MDFjWHZTZmZHZ29PbUNHVE5wQ1d5bzZvU0paMUxxMm1kUnJUTXJHdk81ME9xNUZBQnB2cmtyYlFaWEdRSzAycWV4N3VmaFBrZXp0aldzWFQ0NHpMY2NFM1l5T1VjRkdqMUc5SGNsQnpnMA?oc=5", "source_name": "Market source", "published_at": "2025-09-23T07:00:00+00:00", "published_display": "23 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 83, "total_relevant": 55, "sentiment_summary": {"positive": 11, "negative": 5, "neutral": 39, "score": 53, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 22.15, "count": 39}, {"event": "earnings", "label": "Earnings", "weight": 3.85, "count": 7}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.75, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 3.28, "latest_week": "2026-07-10", "one_week_move": -9.1, "four_week_move": -21.3, "twelve_week_move": -9.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.1156, "market_dynamics_buy_signal": false, "relative_strength": -50.096658, "fair_value_gap": -65.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.8668, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.1% over one week, -21.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "TradingView", "count": 9}, {"label": "Stock Titan", "count": 9}, {"label": "Simply Wall Street", "count": 3}, {"label": "MT Newswires", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "Quiver Quantitative", "count": 3}, {"label": "simplywall.st", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 55}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 39}, {"label": "Earnings", "count": 7}, {"label": "Balance sheet", "count": 5}, {"label": "Analyst action", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "55", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-9.1% over one week, -21.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "ALVO Stock Price Prediction 2025-2026 | Alvotech Forecast"}], "updated_at": "2026-07-16T17:06:19.494372+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}